I[ntroduction]{.smallcaps} {#sec1-1}
==========================

*Enterococci* are one of the major causes of nosocomial infections and bacteremia.\[[@ref1][@ref2]\] They were identified as a cause of community-acquired infections, including pelvic infections, neonatal infections, and urinary tract infections (UTIs). They also cause surgical bacteremia, endocarditis, wound infections, and rarely meningitis.\[[@ref3]\] Most of the clinically significant enterococcal infections are caused by two species, *Enterococcus faecalis* and *Enterococcus faecium*. Recently, the emergence of antimicrobial resistance in *enterococci*, particularly to the glycopeptides, has caused great challenges for clinicians.\[[@ref4][@ref5]\] Antimicrobial therapy of serious enterococcal infection is becoming more complex due to the inherent resistance shown by *enterococci* to several commonly used antibiotics, such as cephalosporins, low-level aminoglycosides, and low-level clindamycin. With the increase in the prevalence of vancomycin-resistant *enterococci* (VRE), there were only a few effective antimicrobial agents left for the management of severe infections and results in the selection and spreading of multidrug-resistant (MDR) strains in hospitals.\[[@ref4][@ref5][@ref6]\] Asymptomatic intestinal colonization by VRE has been associated with multiple risk factors and often precedes true infection.\[[@ref7][@ref8]\] Many countries in Europe, Asia, Australia, South America, and some in Africa reported the increasement in the prevalence of VRE.\[[@ref9][@ref10][@ref11]\] However, there are no enough data available on the prevalence, epidemiology, and risk factors of VRE in Saudi Arabia. The aim of this study was to investigate the risk factors and clinical and epidemiological characteristics of infection with VRE among patients admitted to a university hospital.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Patients {#sec2-1}
--------

This study was carried out on patients with enterococcal infection admitted to King Khalid University Hospital, Riyadh, Saudi Arabia, a tertiary teaching hospital with 850 beds that serves a population of \<1.5 million inhabitants. The study was conducted from September 2014 to November 2015. Prospective investigations were carried out on patients with clinically significant enterococcal infection attending hospital clinics, emergency rooms, medical and surgical wards, and Intensive Care Units (ICUs). For some patients, data were collected retrospectively. Patients might acquire VRE colonization and subsequent infection during current or prior hospitalization. It was not always possible to determine in each single case the source of colonization preceding infection. However, all cases enrolled in this study had a clinically significant infection. All admitted patients were followed prospectively. However, for some patients, retrospective reviews of their files were done to obtain some information on previous admission, underlying diseases, prior VRE bacteremia, and ICUs stay. Patients were followed until discharge or death. Microbiological and clinical information were gathered including age, gender, hospitalization ward (medical wards, surgical wards, or ICU), source of the infection, clinical diagnosis, history of vancomycin intake, surgical interventions, invasive procedure and devices, and current medication profile. This study was approved by the Institutional Ethics Review Board of King Khalid University Hospital.

Bacterial culture: Identification and susceptibility testing {#sec2-2}
------------------------------------------------------------

Clinical specimens included urine, pus, tissue, blood, and body fluids. Surveillance cultures (taken within 24 h after admission) for VRE screening received usually from ICUs such as rectal swabs were excluded. Culture and antibiotic susceptibility of the isolates were performed as per the standard recommendations. The clinical significance of the *Enterococcus* isolates was assessed retrospectively by analyzing the clinical criteria such as catheterization in UTIs, signs of sepsis, and other laboratory tests such as leukocytosis. Colonies isolated from routine clinical specimens resembling *enterococci* were initially identified by Gram-staining, growth in 6.5% NaCl broth, and bile esculin hydrolysis. *In vitro* susceptibilities of the isolates to ampicillin, ciprofloxacin, vancomycin, gentamicin, teicoplanin, and linezolid were determined by the disk diffusion method and interpreted according to *the Clinical and Laboratory Standards Institute (CLSI) guidelines*, *2007*. Care was taken to view the vancomycin zone of inhibition in transmitted light after 24 h of incubation at 37°C.\[[@ref12]\] The minimum inhibitory concentration (MIC) of vancomycin was determined by the E-test for all the *enterococci* isolates, which showed intermediate sensitivity by the Kirby-Bauer disc diffusion method. A lawn culture of *enterococci*, 0.5 McFarland\'s standard, was made on 5% Mueller Hinton blood agar. The E-strip, which was obtained from Himedia^®^, was applied with a MIC scale, facing up, using sterile forceps, with the higher concentration facing the edge of the plate. The plates were examined after 24 h of incubation at 37°C. The zone of inhibition was observed in the form of an ellipse. The antibiotic susceptibility pattern was interpreted as per the CLSI Guidelines, 2007.\[[@ref12]\]

Statistical analysis {#sec2-3}
--------------------

Statistical analyses were performed using SPSS version 19.0 statistical software (SPSS Inc. Wacker Drive, Chicago, IL, USA). Continuous variables were presented as means ± standard deviations (SDs) and were compared using the Student\'s *t*-test. Categorical variables were compared using Chi-squared test or Fisher\'s exact test if the expected values were \<5. A value of *P* \< 0.05 was considered statistically significant.

R[esults]{.smallcaps} {#sec1-3}
=====================

In a 1-year period, 231 *enterococci* were isolated from blood, urine, exudates, sputum, stool, and body fluid (peritoneal, ascetic, bile, and drains) \[[Table 1](#T1){ref-type="table"}\]. Urine in 95 (41.4%) isolates followed by blood 63 (27.2%) and wound swab 45 (19.4) were the most commonly involved specimens. VRE were more significant from blood specimens (*P* \< 0.0001) while VSE were significantly more predominant from urine specimens (*P* \< 0.0001). In all other specimens (body fluid, cerebrospinal fluid, pus, tissue, and wound swab), there was no significant difference in the frequency of isolated VSE and VRE \[[Table 2](#T2){ref-type="table"}\]. The most common isolated *Enterococcus* species was *E. faecalis* 169 (73.2%) followed by *E. faecium* 53 (22.9%). *E. gallinarum* and *E. avium* represented 5 (2.2%) each \[[Figure 1](#F1){ref-type="fig"}\]. There were 191 (82.7%) VSE, and 40 (17.3%) isolates were VRE. Thirty-three (62.3%) of *E. faecium* isolates were vancomycin resistant while only two (1.2%) of *E. faecalis* isolates were vancomycin resistant. The susceptibility pattern of *E. faecalis* and *E. faecium* to other clinically important antibiotics was also analyzed \[[Table 3](#T3){ref-type="table"}\]. *E. faecalis* showed high susceptibility to most tested antimicrobial agents. A high level of gentamicin resistance was seen in 40 (23.7%) of the *E. faecalis* isolates and 36 (67.9%) of *E. faecium* isolates. Linezolid was the most active antibiotic against *E. faecium* followed by teicoplanin and tigecycline. In comparison to vancomycin-susceptible *enterococci* (VSE), VRE were more commonly isolated from patients in ICUs and oncology unit (*P* = 0.0151 and *P* \< 0.001, respectively) whereas VSE were more commonly isolated from patients in medical and surgical wards (*P* = 0.0178, [Figure 2](#F2){ref-type="fig"}). The detailed clinical and microbiological data for patients who acquired VRE while in ICU, oncology, and surgical and medical wards are shown in Tables [4](#T4){ref-type="table"}--[6](#T6){ref-type="table"}, respectively. Overall, 40 VRE patients developed serious or persistent infection including bacteremia (24), wound infection (9), UTI (6), and peritonitis (2). One patient had peritonitis postcolectomy complicated with bacteremia. Intestinal VRE-carriage was identified in three patients admitted to the ICU. The mean age of VRE-infected patients was 55.4 ± 22.0 years. Blood was the most common specimens received from VRE-infected patients in the ICU, oncology, and surgical and medical wards (11/16, 7/12, and 5/12, respectively). Five patients had concomitant infection with organisms other than VRE: Multi-resistant *Acinetobacter baumannii* recovered from the blood of an AIDS patient with Kaposi sarcoma and septic shock, *Enterobacter cloacae* from ascetic fluid of a patient with terminal stage cancer of the colon and peritonitis, multi-resistant *Pseudomonas aeruginosa* from a patient with diabetic foot infection, nonidentified Gram-negative *Bacilli* from the blood of a patient with adenocarcinoma of the gallbladder, and extended-spectrum beta-lactamases producing *Escherichia coli* from ascetic fluid of a patient with liver disease. Thirteen of the VRE-infected patients (32.5%) for whom the treatment information was available received vancomycin prior or during the course of infection.

###### 

Type of specimens from which *enterococci* were isolated

  Type of specimen      All enterococcal species (*n* = 231)
  --------------------- --------------------------------------
  Blood                 64 (27.7)
  Body fluid            18 (7.8)
  Cerebrospinal fluid   1 (0.4)
  Pus                   1 (0.4)
  Tissue                6 (2.6)
  Urine                 95 (41.4)
  Wound swab            46 (19.9)

Data are presented as *n* (%).

###### 

Distribution of specimens among VRE and VSE

  Type of specimen   VSE (*n* = 191)   VRE (*n* = 40)   *χ*^2^   *P*
  ------------------ ----------------- ---------------- -------- ----------
  Blood              41 (21.5)         23 (57.5)        21.44    \<0.0001
  Body fluid         16 (8.4)          2 (5.0)          0.525    0.469
  CSF                1 (0.5)           0                0.210    0.647
  Pus                1 (0.5)           0                0.210    0.647
  Tissue             6 (3.1)           0                1.290    0.256
  Urine              89 (46.6)         6 (15.0)         13.637   \<0.0001
  Wound swab         37 (19.4)         9 (22.5)         0.203    0.652

Data are presented as *n* (%). CSF: Cerebral spinal fluid; VRE: Vancomycin-resistant *enterococci*; VSE: Vancomycin-sensitive *enterococci*.

![Frequency of different *enterococci* isolated from hospitalized patients.](CMJ-130-340-g001){#F1}

###### 

Susceptibility pattern of *E. faecalis* and *E. faecium* to clinically important antibiotics

  Species (number tested)   Antimicrobial   GM          TP           VAN          AMP          CIP          TEG          LZD          NIT
  ------------------------- --------------- ----------- ------------ ------------ ------------ ------------ ------------ ------------ -----------
  *E*. *faecium* (53)       R               36 (67.9)   15 (28.3)    33 (62.3)    51 (96.2)    40 (75.5)    16 (30.2)    6 (11.3)     29 (54.7)
  S                         17 (32.1)       38 (71.7)   20 (37.7)    2 (3.8)      13 (24.5)    37 (69.8)    47 (88.7)    24 (45.3)    
  *E. faecalis* (168)       R               40 (23.7)   0            2 (1.2)      6 (3.6)      38 (23.1)    10 (6.5)     11 (7.1)     22 (13.0)
  S                         128 (76.3)      168 (100)   166 (98.8)   162 (96.4)   130 (76.9)   158 (93.5)   157 (92.9)   147 (87.0)   

Data are presented as *n* (%). GM: Gentamycin; TP: Teicoplanin; VAN: Vancomycin; AMP: Ampicillin; CIP: Ciprofloxacin; TEG: Tigecycline; LZD: Linezolid; NIT: Nitrofurantoin; *E. faecalis*: *Enterococcus faecalis*; *E. faecium*: *Enterococcus faecium*; R: Resistant; S: Sensitive.

![Distribution of VSE and VRE in hospital wards. VRE: Vancomycin-resistant *enterococci*; VSE: Vancomycin-sensitive *enterococci*.](CMJ-130-340-g002){#F2}

###### 

Clinical characteristics and microbiological details of VRE infected patients admitted to the ICU

  Age (years)   Gender   Specimen     Clinical data                                   *Enterococcus spp*.   Resistance phenotype   VAN (μg/ml)   TP (μg/ml)   LZD   Treatment
  ------------- -------- ------------ ----------------------------------------------- --------------------- ---------------------- ------------- ------------ ----- -------------
  3             Female   Blood        Short bowel syndrome-pleural effusion           *E. faecium*          VAN A                  \>256         \>256.00     S     NA
  59            Male     Blood        IHD-CAP-fever-DM-HF                             *E. faecium*          NA                     \>16          1.00         S     TAZ-CRO-AZT
  34            Male     Blood        AIDS-PCP-Kaposi sarcoma, septic shock           *E. faecium*          VAN A                  \>256         16.00        S     NA
  35            Male     Blood        CML, fever                                      *E. faecium*          VAN B                  32            0.25         S     COL, VAN
  65            Male     Urine        P-CABG                                          *E. faecium*          VAN B                  16            1.00         R     VAN + MER
  34            Female   Blood        AML-central line                                *E. faecium*          VAN A                  \>256         \>256.00     S     AK-CAZ-VAN
  67            Female   Wound swab   Postlaparotomy                                  *E. faecium*          NA                     16            1.00         S     MER-LZD
  62            Female   Blood        Postcardiac surgery, tracheostomy               *E. faecium*          VAN A                  \>256         \>256.00     S     NA
  82            Male     Blood        Postlaparotomy                                  *E. faecium*          VAN B                  \>32          \>16.00      S     NA
  72            Female   Blood        P-CABG                                          *E. faecium*                                 \>16/24       0.75         S     MER-VAN
  44            Male     Wound swab   DM, HTN, sacral infected wound                  *E. faecium*          VAN B                  \>16          0.25         S     MER-VAN
  75            Female   Blood        Brachial artery thrombosis                      *E. faecium*          VAN B                  \>16          \>0.25       S     VAN
  1             Female   Blood        Brain tumor, neutropenia, fever, chemotherapy   *E. faecium*          NA                     \>32          \>32.00      S     NA
  2\*           Female   Blood        Short bowel syndrome-fever                      *E. gallinarum*       NA                     6             1.00         S     VAN + MTZ
  77            Male     Wound swab   Septic arthritis, fever                         *E. gallinarum*       NA                     16            1.00         S     NA
  33            Female   Wound swab   Polymyositis                                    *E. gallinarum*       NA                     4             0.25         S     NA

\*2 months old. P-CABG: Postcoronary artery bypass grafting; DM: Diabetes mellitus; HTN: Hypertension; IHD: Ischemic heart disease; HF: Heart failure; CAP: Community acquired pneumonia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia, AIDS: Acquired immune deficiency syndrome; PCP: *Pneumocystis carinii* pneumonia; NA: Not available; TAZ: Tazocin (piperacillin and tazobactam); CRO: Ceftriaxone; AZT: Aztreonam; VAN: Vancomycin; MTZ: Metronidazole; MER: Meropenem; LZD: Linezolid; AK: Amikacin; CAZ: Ceftazidime; COL: Colistin; R: Resistant; S: Sensitive; VRE: Vancomycin-resistant *enterococci*; *E. faecium*: *Enterococcus faecium*; *E. gallinarum*: *Enterococcus gallinarum*; TP: Teicoplanin; ICU: Intensive Care Unit.

###### 

Clinical characteristics and microbiological details of VRE patients admitted to oncology wards

  Age (years)   Gender   Specimen                Clinical data                                                            *Enterococcus Spp*.   Resistance phenotype   VAN (mg/ml)   TP (mg/ml)   LZD   Treatment
  ------------- -------- ----------------------- ------------------------------------------------------------------------ --------------------- ---------------------- ------------- ------------ ----- -------------
  59            Male     Blood                   CA-breast, chemotherapy, peritoneal metastasis                           *E. faecium*          VAN B                  \>16--24      0.25         S     VAN + TAZ
  75            Female   Ascetic fluid + blood   Terminal CA-colon, colectomy, stoma infection, fever                     *E. faecium*          VAN B                  32            0.57         S     CIP-AMP TP
  63            Female   Blood                   CA-pancreas, DM, postoperative, fever                                    *E. faecium*          VAN B                  16            1.00         R     CXM-MTZ
  64            Female   Blood                   CA-breast-postmastectomy, chemotherapy, fever -neutropenia               *E. faecium*          VAN A                  \>256         24.00        S     NA
  60            Female   Blood                   Cholangiocarcinoma, fever, postcholecystectomy, metastasis-peritonitis   *E. faecium*          VAN B                  16            1.00         S     MER-LZD-CRO
  40            Male     Blood                   Multiple myeloma                                                         *E. faecium*          VAN B                  16            \>0.38       S     AN
  30            Male     Wound swab              CA-stomach, postgastrectomy, wound infection                             *E. gallinarum*       VAN B                  \>32          0.75         S     VAN + CIP
  60            Female   Urine                   CA-esophagus                                                             *E. faecium*          VAN A                  \>256         \>16.00      S     VAN
  80            Male     Urine                   Multiple myeloma                                                         *E. faecium*          VAN B                  \>16          0.38         S     NA
  25            Female   Blood                   AML                                                                      *E. faecium*          VAN B                  \>16          1.00         S     NA
  43            Female   Blood                   Lymphoma                                                                 *E. faecium*          VAN B                  \>16          1.00         S     NA
  91            Male     Urine                   CA-prostate-bone metastasis                                              *E. faecium*          VAN B                  \>16          0.25         S     NA

CA: Cancer; AML: Acute myeloid leukemia; CXM: Cefuroxime; MER: Meropenem; TAZ: Tazocin (piperacillin and tazobactam); CRO: Ceftriaxone; VAN: Vancomycin; MTZ: Metronidazole; LZD: Linezolid; AMP: Ampicillin; CIP: Ciprofloxacin; TP: Teicoplanin; R: Resistant; S: Sensitive; NA: Not available; VRE: Vancomycin-resistant *enterococci*; *E. faecium*: *Enterococcus faecium*; *E. gallinarum*: *Enterococcus gallinarum*.

###### 

Clinical characteristics and microbiological details of VRE patients admitted to medical and surgical wards

  Age (years)   Gender   Specimen     Clinical data                 *Enterococcus* spp.   Resistance phenotype   VAN (mg/ml)   TP (mg/ml)   LZD   Treatment
  ------------- -------- ------------ ----------------------------- --------------------- ---------------------- ------------- ------------ ----- -----------
  69            Female   Blood        Massive pulmonary embolism    *E. faecium*          VAN B                  16            0.25         S     NA
  73            Female   Blood        IHD-DM, HTN                   *E. faecalis*         VAN B                  4             0.38         S     NA
  54            Female   Wound swab   Postlaparotomy                *E. faecium*          VAN B                  \>16          1.00         S     MER-VAN
  50            Male     Wound swab   DM, infected diabetic wound   *E. faecium*          VAN B                  \>24          0.75         S     MER-VAN
  58            Male     Blood        Postsplenectomy               *E. gallinarum*       VAN B                  6             1.00         S     AN
  68            Female   Body fluid   Ascites+liver disease         *E. faecium*          VAN B                  12            0.25         S     NA
  73            Male     Wound swab   Postsurgery                   *E. faecium*          VAN A                  \>256         16.00        S     VAN+TAZ
  66            Female   Urine        Vomiting, vaginal bleeding    *E. faecium*          VAN B                  \>16          0.25         S     NA
  71            Male     Urine        Postcraniotomy                *E. faecium*          VAN B                  4             0.25         S     NA
  57            Male     Blood        Fever                         *E. faecalis*         VAN B                  4             0.25         S     NA
  77            Male     Blood        IHD, CVA, encephalopathy      *E. faecium*          VAN B                  \>16          0.38         S     NA
  65            Male     Wound swab   Postsurgery                   *E. faecium*          VAN B                  \>16          1.00         S     NA

IHD: Ischemic heart disease; DM: Diabetes mellitus; HTN: Hypertension; CVA: Cerebrovascular accidents; VAN: Vancomycin, MER: Meropenem; TAZ: Tazocin (piperacillin and tazobactam); TP: Teicoplanin; LZD: Linezolid; R: Resistant; S: Sensitive; NA: Not available; *E. faecium*: *Enterococcus faecium*;*E. gallinarum*: *Enterococcus gallinarum*; *E. faecalis*: *Enterococcus faecalis*; VRE: Vancomycin-resistant *enterococci*.

D[iscussion]{.smallcaps} {#sec1-4}
========================

In the present study, the overall prevalence of *enterococci* was 231 isolates. In a study from Riyadh, a total of 206 *enterococci* were isolated from 240 patients with nosocomial infections, with specimens collected from in-patients and out-patients at King Khalid University Hospital (140 specimens) and King Saud Medical City Hospital (100 specimens).\[[@ref13]\] The prevalence of VRE in this study is 17.3%, consistent with a report from a hospital in Brazil (15.8%).\[[@ref14]\] A higher isolation rate of VRE was reported from Iran (23.7%) and from pediatric hematology/oncology patients in Egypt (75.0%).\[[@ref15][@ref16]\] These differences might be due to the study design and study population (pediatric age) in the previous study. A study from a University Hospital in Belgium revealed even a higher incidence of VRE 586/1260 (46.5%).\[[@ref17]\] In a recent national surveillance of antimicrobial resistance among Gram-positive *Bacteria* in Saudi Arabia involving 13750 isolates, *enterococci* account only for 3~·~1%.\[[@ref18]\] In Europe, surveillance data showed variable VRE rates among different countries ranging from \<2.0% (Finland, Holland) to \>20% (Ireland, Greece, Portugal). Italy is a country with a low rate level (4.2%).\[[@ref19]\] Rates of VRE in the USA hospitals reached 33.0%.\[[@ref20]\] Similar to other studies, we found that the maximum number of isolates were obtained from urine followed by blood and wound swab.\[[@ref13][@ref14][@ref15]\] However, in one study, the maximum number of isolates were obtained from pus (43.0%), followed by urine (31.0%).\[[@ref21]\] More interestingly, we found that blood was the most common specimens received from VRE-infected patients in the ICU, oncology, and surgical and medical wards. Most of those patients were critically ill. Several studies have shown that infections caused by VRE, particularly bloodstream infections, are more serious and associated with higher mortality rate compared to those caused by vancomycin-susceptible *enterococci* (VSE).\[[@ref22][@ref23][@ref24]\] Moreover, we found that 30.0% (12/40) of our VRE-infected patients were oncology patients and 40.0% (16/40) were ICU patients. Screening for and identifying VRE colonization prior to ICU and oncology wards will provide an opportunity to initiate strict infection control measures and prevent nosocomial transmission. In a retrospective review of 2115 cancer and transplant recipient patients, VRE fecal colonization was documented in 5.4% of patients with leukemia, 4.9% of hematopoietic stem cell transplantation recipients, and 2.2% of patients with lymphoma. Twenty-nine (29.3%) of those developed bacteremia.\[[@ref25]\] The *Enterococcus* isolates obtained in the study were mostly *E. faecalis* (72.4%) followed by *E. faecium* (22.8%). This species distribution is similar to that reported from a regional study in which among 206 of enterococcal isolates, 166 (69.2%) were identified as *E. faecalis* and 27 (11.3%) as *E. faecium*.\[[@ref13]\] Sreeja *et al*.\[[@ref21]\] reported a similar result in their study that *E. faecalis* (76.0%) formed the major isolate, followed by *E. faecium* (24.0%). Similarly, in a study from Iran, 106 (57.0%) isolates were identified as *E. faecalis* and 80 (43.0%) of the isolates were identified as *E. faecium*.\[[@ref15]\] An increase in the isolation rate of *E. faecium* and other non-*faecalis* species of *Enterococcus* was found in one study.\[[@ref26]\] It has been well documented that ICUs are major reservoirs of VRE in the health care setting.\[[@ref27]\] VRE colonization on admission to the ICU is a major determinant of VRE infection. In a meta-analysis of published studies to assess trends of VRE colonization in the ICU, 7.1--10.6% of patients admitted to the ICU were colonized with VRE on admission.\[[@ref28]\] The risk of VRE infection in the ICU among colonized patients (0--45.0%) was higher than the risk of VRE infection among noncolonized cases (\<2.0%). Susceptible populations, such as solid organ transplant recipients,\[[@ref29]\] cancer patients,\[[@ref25]\] and allogeneic hematopoietic stem cell transplant recipients,\[[@ref30]\] are at greatest risk of colonization and subsequent infection and bacteremia. In addition, VRE colonization was identified in 184 ICU patients (17.6%) for whom routine perianal swab cultures were obtained on ICU admission to a tertiary hospital in Korea.\[[@ref31]\] Of these, 11.9% developed VRE infection. Interestingly, in the study, there was a greater prevalence of VRE among patients admitted in the ICU and oncology areas. These results are in agreement with that reported in a Saudi study which recovered 85.0% of the total VRE isolates from the ICU; 112 (46.7%) from the surgical ward, 67 (27.9%) and 27 (11.3%) from the internal medicine ward.\[[@ref13]\] The same finding was reported from Brazil, in which the maximum prevalence of VRE was found in patients admitted in ICUs (38.2%), followed by the emergency ward (23.5%).\[[@ref14]\] More important, nearly 69.0% of ICU patients in the study developed septicemia. Almost all of these patients were critically ill with complex underlying pathology. The presence of severe comorbidity and combined infection with organisms other than VRE are possible risk factors for the development of VRE bacteremia in our ICU patients. Four of the VRE isolates recovered from the ICU patients were highly resistant to vancomycin and all were of the *E. faecium* species. Varying levels of resistance was seen to various antibiotics. Most of the *E. faecium* isolates were resistant to ampicillin (96.0%) with the least resistance level to linezolid (11.3%). On the other hand, compared to *E. faecium*, *E. faecalis* showed a more susceptible antimicrobial profile to all tested antibiotics. Our VRE-infected patients have limited therapeutic options to other clinically useful antibiotics, including teicoplanin, ciprofloxacin, and high-level gentamicin, leading to potentially more serious outcome and high fatality.

This study had several limitations. First, we had a relatively small number of studied patients, thus reducing the statistical power of the results. Second, we had difficulty in determining VRE infection versus colonization from current or prior hospitalization for each individual case. Third, there was a lack of molecular studies that might have led to a better understanding of the epidemiology and source of infection of VRE-colonized or infected patients.

In conclusion, the presence of high prevalence of VRE in this study signals the emergence of more VRE-infected patients, particularly in critical areas such as ICUs and oncology units. Therefore, the rational use of antibiotics and a more detailed study using phenotypic and genotypic methods are needed.

Financial support and sponsorship {#sec2-4}
---------------------------------

Nil.

Conflicts of interest {#sec2-5}
---------------------

There are no conflicts of interest.

**Edited by:** Peng Lyu
